Demonstration of Direct Nose-to-Brain Transport of Unbound HIV-1 Replication Inhibitor DB213 Via Intranasal Administration by Pharmacokinetic Modeling

No abstract is available for this paper.

• Publication year

  2017

• Venue

  AAPS Journal

• Publication date

  2017-12-27

• Fields of study

  Medicine

• Identifiers
  DOI 10.1208/s12248-017-0179-0PMID 29282567
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Peripheral Administration of a Long-Acting Peptide Oxytocin Receptor Agonist Inhibits Fear-Induced Freezing

  2016cited by this paper
• A Generic Multi-Compartmental CNS Distribution Model Structure for 9 Drugs Allows Prediction of Human Brain Target Site Concentrations

  2016cited by this paper
• Pharmacokinetics and brain uptake of HIV-1 replication inhibitor DB213 in Sprague-Dawley rats.

  2016cited by this paper
• Pharmacokinetic Concepts in Brain Drug Delivery

  2014cited by this paper
• Pharmacokinetic Comparison Between the Long-Term Anesthetized, Short-Term Anesthetized and Conscious Rat Models in Nasal Drug Delivery

  2014cited by this paper
• Insights into direct nose to brain delivery: current status and future perspective

  2014cited by this paper
• Controversies in HIV-associated neurocognitive disorders.

  2014cited by this paper
• Quantitative analysis of drug delivery to the brain via nasal route.

  2014cited by this paper
• Utility of CSF in translational neuroscience

  2013cited by this paper
• Intranasal Insulin as a Treatment for Alzheimer’s Disease: A Review of Basic Research and Clinical Evidence

  2013cited by this paper
• Utility of CSF in translational neuroscience

  2013cited by this paper
• Intranasal delivery of biologics to the central nervous system.

  2012cited by this paper
• Pharmacokinetics and brain dispositions of tacrine and its major bioactive monohydroxylated metabolites in rats.

  2012cited by this paper
• Systemic and Direct Nose-to-Brain Transport Pharmacokinetic Model for Remoxipride after Intravenous and Intranasal Administration

  2011cited by this paper
• Intranasal administration of milnacipran in rats: evaluation of the transport of drugs to the systemic circulation and central nervous system and the pharmacological effect.

  2011cited by this paper
• Prediction-Corrected Visual Predictive Checks for Diagnosing Nonlinear Mixed-Effects Models

  2011cited by this paper
• Active-site concentrations of chemicals - are they a better predictor of effect than plasma/organ/tissue concentrations?

  2010cited by this paper
• HIV-Associated Neurocognitive Disorder: Pathogenesis and Therapeutic Opportunities

  2010cited by this paper
• Structure-brain exposure relationships in rat and human using a novel data set of unbound drug concentrations in brain interstitial and cerebrospinal fluids.

  2009cited by this paper
• Intranasal delivery of cells to the brain.

  2009cited by this paper
• Intranasal Administration of Alpha Interferon Reduces Seasonal Influenza A Virus Morbidity in Ferrets

  2009cited by this paper
• Multiplicity of cerebrospinal fluid functions: New challenges in health and disease

  2008cited by this paper
• Evaluation of Direct Transport Pathways of Glycine Receptor Antagonists and an Angiotensin Antagonist from the Nasal Cavity to the Central Nervous System in the Rat Model

  2008cited by this paper
• Can Nasal Drug Delivery Bypass the Blood-Brain Barrier?

  2007cited by this paper
• Use of Plasma and Brain Unbound Fractions to Assess the Extent of Brain Distribution of 34 Drugs: Comparison of Unbound Concentration Ratios to in Vivo P-Glycoprotein Efflux Ratios

  2007cited by this paper
• In Vitro Methods for Estimating Unbound Drug Concentrations in the Brain Interstitial and Intracellular Fluids

  2007cited by this paper
• Pharmacokinetics and Pharmacodynamics of Seven Opioids in P-Glycoprotein-Competent Mice: Assessment of Unbound Brain EC50,u and Correlation of in Vitro, Preclinical, and Clinical Data

  2007cited by this paper
• Direct Nose-to-Brain Transfer of Morphine After Nasal Administration to Rats

  2006cited by this paper
• Distribution of Zolmitriptan into the CNS in Healthy Volunteers

  2005cited by this paper
• The blood-brain barrier: Bottleneck in brain drug development

  2005cited by this paper
• A microdialysis model to examine nasal drug delivery and olfactory absorption in rats using lidocaine hydrochloride as a model drug.

  2004cited by this paper
• The potential of nasal application for delivery to the central brain-a microdialysis study of fluorescein in rats.

  2004cited by this paper
• Delivery of insulin-like growth factor-I to the rat brain and spinal cord along olfactory and trigeminal pathways following intranasal administration.

  2004cited by this paper
• Influence of nonspecific brain and plasma binding on CNS exposure: implications for rational drug discovery

  2002cited by this paper
• Measurement of fraction unbound paclitaxel in human plasma.

  2000cited by this paper
• Transfer of Dopamine in the Olfactory Pathway Following Nasal Administration in Mice

  2000cited by this paper
• Effects of methoxyflurane anesthesia on the pharmacokinetics of 125I-IAZA in Sprague-Dawley rats.

  1999cited by this paper
• Transfer of some carboxylic acids in the olfactory system following intranasal administration.

  1999cited by this paper
• Gene delivery into the central nervous system by nasal instillation in rats.

  1995cited by this paper
• Labeling of Cerebral Amyloid In Vivo with a Monoclonal Antibody

  1994cited by this paper
• In Vivo Transport of a Dynorphin-like Analgesic Peptide, E-2078, Through the Blood–Brain Barrier: An Application of Brain Microdialysis

  1991cited by this paper
• Blood volume in the rat.

  1985cited by this paper
• Environmental Research and Public Health Pm 2.5 -induced Oxidative Stress and Mitochondrial Damage in the Nasal Mucosa of Rats

  year unknowncited by this paper

• Overcoming translational barriers in nose-to-brain drug delivery for clinical applications.

  2026cites this paper
• Challenges and Opportunities for Incorporating Physiological Information into Pharmacokinetic Models of Intranasal Drug Delivery to the Brain: A Review of the Current Status and Future Trajectories.

  2025cites this paper
• Uniform Spray Dried Loxapine Microparticles Potentially for Nasal Delivery: Exploring Discriminatory In Vitro Release Evaluation Methods

  2025cites this paper
• Revolutionizing Parkinson’s treatment: Harnessing the potential of intranasal nanoemulsions for targeted therapy

  2025cites this paper
• Phenylboronic Acid-Functionalized Chitosan for Enabling Transmucosal Delivery for Cancer Therapy

  2023cites this paper
• Intranasal delivery of darunavir improves brain drug concentrations in mice for effective HIV treatment

  2022cites this paper
• Neuroprotection by resveratrol: A review on brain delivery strategies for Alzheimer’s and Parkinson’s disease

  2022influential citation
• Nasal Delivery of AntagomiR-741 Protects Against the Radiation-Induced Brain Injury in Mice

  2021cites this paper
• CAG RNAs induce DNA damage and apoptosis by silencing NUDT16 expression in polyglutamine degeneration

  2021cites this paper
• Nose-to-brain delivery of antiretroviral drugs against NeuroAIDS

  2021cites this paper
• Intranasal Delivery of Nanoformulations: A Potential Way of Treatment for Neurological Disorders

  2020cites this paper
• Nose to brain delivery of nanocarriers towards attenuation of demented condition.

  2020cites this paper
• Nose-to-Brain Delivery

  2019cites this paper
• Targeted drug delivery to the brain via intranasal nanoemulsion: Available proof of concept and existing challenges.

  2019cites this paper
• Efficient brain uptake and distribution of an expanded CAG RNA inhibitor DB213 via intranasal administration

  2019cites this paper
• Baclofen-Loaded Poly (D,L-Lactide-Co-Glycolic Acid) Nanoparticles for Neuropathic Pain Management: In Vitro and In Vivo Evaluation

  2019cites this paper
• Exclusion of unsuitable CNS drug candidates based on their physicochemical properties and unbound fractions in biomatrices for brain microdialysis investigations.

  2019cites this paper
• Intranasal delivery of a novel acetylcholinesterase inhibitor HLS‐3 for treatment of Alzheimer's disease

  2018cites this paper
• Statistical Design of Experiment (DoE) based development and optimization of DB213 in situ thermosensitive gel for intranasal delivery.

  2018cites this paper